3KCK

A Novel Chemotype of Kinase Inhibitors

3KCK の概要

• エントリーDOI: 10.2210/pdb3kck/pdb
• 分子名称: Tyrosine-protein kinase JAK2, 3-chloro-4-(4H-3,4,7-triazadibenzo[cd,f]azulen-6-yl)phenol (3 entities in total)
• 機能のキーワード: kinase, inhibitor, jak2, janus kinase, atp-binding, chromosomal rearrangement, disease mutation, membrane, nucleotide-binding, phosphoprotein, polymorphism, proto-oncogene, sh2 domain, transferase, tyrosine-protein kinase
• 由来する生物種: Homo sapiens (human)
• 細胞内の位置: Endomembrane system; Peripheral membrane protein (By similarity): O60674
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 37128.59

構造登録者

Zuccola, H.J.,Wang, T.,Ledeboer, M.W. (登録日: 2009-10-21, 公開日: 2009-11-24, 最終更新日: 2024-11-06)

主引用文献

Wang, T.,Ledeboer, M.W.,Duffy, J.P.,Pierce, A.C.,Zuccola, H.J.,Block, E.,Shlyakter, D.,Hogan, J.K.,Bennani, Y.L.
A novel chemotype of kinase inhibitors: Discovery of 3,4-ring fused 7-azaindoles and deazapurines as potent JAK2 inhibitors.
Bioorg.Med.Chem.Lett., 20:153-156, 2010

PubMed Abstract: Pictet-Spengler condensation of aldehydes or alpha-keto-esters with 4-(2-anilinophenyl)-7-azaindole (11) or deazapurine (12) gave high yields of the 3,4-fused cyclic compounds. SAR studies, by varying the substituted benzaldehyde components, lead to the discovery of a series of potent JAK2 kinase inhibitors.

PubMed: 19945871
DOI: 10.1016/j.bmcl.2009.11.021

実験手法

X-RAY DIFFRACTION (2.2 Å)